Real-world evidence: Methods for assessing long-term health and effectiveness of allergy immunotherapy - 03/03/22
Doi : 10.1016/j.jaci.2021.12.781
Benedikt Fritzsching, MD, Prof (apl) Dr a, ⁎ 
, Marco Contoli, MD, PhD b, Celeste Porsbjerg, MD, PhD c, Sarah Buchs, MSc d, Julie Rask Larsen, MD, PhD d, Nick Freemantle, PhD e
, Marco Contoli, MD, PhD b, Celeste Porsbjerg, MD, PhD c, Sarah Buchs, MSc d, Julie Rask Larsen, MD, PhD d, Nick Freemantle, PhD e a Paediatric Pulmonology and Allergy, Children’s Doctor Service, University of Heidelberg, Heidelberg, Germany
b Respiratory Section, Department of Translational Medicine, University of Ferrara, Ferrara, Italy
c Department of Respiratory Medicine, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
d ALK-Abelló, Hørsholm, Denmark
e Institute of Clinical Trials and Methodology UCL, London, United Kingdom
∗Corresponding author: Benedikt Fritzsching, MD, Pediatric Pulmonology and Allergy, Children’s Doctor Service, Langer Anger 33, 69115 Heidelberg, Germany.Pediatric Pulmonology and AllergyChildren’s Doctor ServiceLanger Anger 33Heidelberg69115Germany
Key words : Allergic rhinitis, allergy, allergy immunotherapy, asthma, effectiveness, long-term follow-up, methodology, RCT, real-world evidence, retrospective cohort study, study design
Le texte complet de cet article est disponible en PDF.
Plan
| Disclosure of potential conflict of interest: B. Fritzsching reports personal fees (for travel to study meetings) from ALK during conduct of the REACT study, as well as speaker honoraria from Novartis and Merck Sharp & Dohme outside the submitted work. M. Contoli reports personal fees from Alk-Abelló during conduct of the study and grants; in addition, he reports personal fees and nonfinancial support from Chiesi and GlaxoSmithKline; personal fees and nonfinancial support from AstraZeneca, Boehringer Ingelheim, Novartis, and Zambon; and grants from University of Ferrara - Italy outside the submitted work. C. Porsbjerg reports grants from ALK, as well as grants and personal fees from AstraZeneca, GSK, Novartis, Chiesi, Sanofi, and TEVA outside the submitted work. S. Buchs reports being employed at ALK-Abelló. J. R. Larsen reports being an employee of ALK. N. Freemantle reports personal fees from AstraZeneca, Ipsen, Sanofi Aventis, Grifols, Novartis, Aimmune Therapeutics, Vertex, MSD, and Allergan outside the submitted work |
© 2021
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 149 - N° 3
P. 881-883 - mars 2022 Retour au numéro
Article précédent
- News Beyond Our Pages
- Marc E. Rothenberg, Jean Bousquet
- Managing risk of anaphylaxis in patients receiving allergen immunotherapy: Assessing benefit versus risk
- David I. Bernstein, Tolly G. Epstein
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?